Results 101 to 110 of about 4,877,471 (249)

Efficacy of Momelotinib in Myelofibrosis Patients: Results From a Multicenter Study

European Journal of Haematology, EarlyView.
ABSTRACT Momelotinib, a novel JAK1/2 inhibitor with inhibitory activities on activin A receptor type I, has shown breakthrough clinical efficacy in patients with myelofibrosis (MF) and anemia, a disease‐related manifestation of challenging management. In this retrospective real‐life multicenter Italian study, we investigated the safety and efficacy of ...
Maria Carmen Martorelli, Novella Pugliese, Maria Di Perna, Danilo De Novellis, Assunta Lombardi, Laura De Fazio, Giuseppina Loglisci, Ilaria Peluso, Matteo Molica, Carolina Copia, Alessandra Ricco, Antonella Bruzzese, Francesco Mendicino, Vincenza De Fazio, Teresa Maria Santeramo, Rosario Bianco, Giuseppe Monaco, Raffaele Fontana, Roberto Guariglia, Bianca Serio, Serena Luponio, Anna Maria Della Corte, Antonella Malandrini, Valentina Giudice, Ferdinando Frigeri, Giuseppe Tarantini, Attilio Guarini, Massimo Gentile, Pellegrino Musto, Mario Annunziata, Nicola Di Renzo, Marco Rossi, Catello Califano, Fabrizio Pane, Carmine Selleri   +34 more
wiley   +1 more source

Primary autoimmune myelofibrosis: a report of three cases and review of the literature

Turkish Journal of Hematology, 2009
Myelofibrosis in association with autoimmune disorders has been consistently recognized in sporadic case reports over a number of years. Autoimmune myelofibrosis has been described most commonly in association with systemic lupus erythematosus (SLE).
Rakhee Kar, Shyamali Dutta, Seema Tyagi
doaj  

Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow

Haematologica, 2012
We investigated 15,542 patients with suspected BCR-ABL1- negative myeloproliferative or myelodysplastic/myeloproliferative neoplasm (including 359 chronic myelomonocytic leukemia) by a molecular marker set.
Susanne Schnittger, Ulrike Bacher, Christiane Eder, Frank Dicker, Tamara Alpermann, Vera Grossmann, Alexander Kohlmann, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach   +9 more
doaj   +1 more source

Myeloproliferative neoplasms: a review of diagnostic criteria and clinical aspects [PDF]

, 2010
Chronic myeloproliferative disorders, currently called myeloproliferative neoplasms (MPN), according to the 4th edition of the World Health Organization (WHO) classification are clonal diseases of hematopoietic stem cells, in which there is increased ...
Chauffaille, Maria de Lourdes Lopes Ferrari
core   +1 more source

Clonal Progression and Leukemic Transformation of a TP53 Mutated Post‐Polycythaemia Vera Myelofibrosis

European Journal of Haematology, EarlyView.
ABSTRACT Previous studies investigating the role of TP53 mutations in chronic phase MPN have yielded inconsistent results. As such, the clinical relevance of these mutations remains to be elucidated. We report a case of a 67‐year‐old woman with a leukemic transformation of a post‐polycythaemia vera myelofibrosis (post‐PV MF) that culminated in the rare
Isidor Minović, Bart Koopman, Joris J. W. Ploegmakers, Elise M. J. van der Logt, Arjen H. G. Cleven, Anouk van der Veen, Arjan Buijs, André B. Mulder, Emanuele Ammatuna   +8 more
wiley   +1 more source

Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies [PDF]

, 2015
Gene expression profiling has implicated several intracellular signalling cascades, including the JAK/STAT pathway, in the pathogenesis of particular subtypes of lymphoma.
Gandhi, Maher K., Scott, Linda M.
core   +1 more source

Leptin receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis

Nature Cell Biology, 2017
Bone marrow fibrosis is a critical component of primary myelofibrosis (PMF). However, the origin of the myofibroblasts that drive fibrosis is unknown.
M. Decker, Leticia Martínez-Morentin, Guannan Wang, Yeojin Lee, Qingxue Liu, Juliana Leslie, Lei Ding   +6 more
semanticscholar   +1 more source

JAK Inhibition Prevents Bone Loss and Reduces Inflammation in Experimental Periodontitis

Journal of Periodontal Research, EarlyView.
The pharmacological inhibition of JAK prevented alveolar bone loss and protected periodontal tissues by limiting inflammatory cell infiltration, preserving collagen structure, and maintaining low levels of pro‐inflammatory mediators. These findings highlight the therapeutic potential of targeting JAK/STAT signaling to modulate periodontal inflammation ...
Mariely A. Godoi, Fábio R. M. Leite, Angelo C. Camilli, Karen G. A. Gonzales, Vitória B. Costa, Iolanda A. F. de Matos, Evangelos Papathanasiou, Morgana R. Guimarães‐Stabili   +7 more
wiley   +1 more source

Colorectal Liver Metastasis, Primary Gallbladder Carcinoma and Myelofibrosis Present Simultaneously in a Liver Resection Specimen

Case Reports in Gastroenterology, 2015
Myelofibrosis and gallbladder carcinoma are both very rare diseases. This case report describes a patient with a history of myelofibrosis and colorectal carcinoma who was diagnosed with colorectal liver metastases.
Sophie A. Gray, Menno H. Raber, Esther Provoost, Gert-Jan Toes, Joost M. Klaase   +4 more
doaj   +1 more source

BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms. [PDF]

, 2013
Small molecule inhibition of the BET family of proteins, which bind acetylated lysines within histones, has been shown to have a marked therapeutic benefit in pre-clinical models of mixed lineage leukemia (MLL) fusion protein-driven leukemias.
Bannister, AJ, Barbieri, I, Calero-Nieto, FJ, Cannizzaro, E, Dawson, MA, Godfrey, A, Gottgens, B, Green, AR, Huntly, B, Kouzarides, T, Li, J, Nangalia, J, Prinjha, RK, Rioja, I, Robson, S, Wiese, M, Wyspiańska, BS   +16 more
core   +1 more source